Post-earnings recap
Reported
Thu, Nov 2, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
PTC Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock still saw a slight increase of 0.45%, likely due to investor optimism about the company's ongoing projects and pipeline advancements. The lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.82 | N/A | -26.75% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to ongoing projects and research.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline despite the earnings miss.